RoActemra wins EU approval for early RA Save

Swiss drugmaker Roche Holding AG said on Monday the European Union has approved the use of its drug RoActemra in patients with early-stage rheumatoid arthritis. Roche said the European Commission has backed RoActemra as a treatment for patients with severe, active and progressive rheumatoid arthritis who have previously not been treated with methotrexate.